BOOK EARLY AND SAVE UP TO £600

December 4-6, London, UK

www.tumour-models.com

7th PREDICT: TUMOUR MODELS LONDON

Enhancing the Translational Confidence of Models Based Research

Expert speakers include:

Elizabeth Hardaker
Head, Oncology In Vivo Pharmacology Group
AstraZeneca

Gavin Bennett
Head of Preclinical Development
Bicycle Therapeutics

Ayako Pedersen
Head of Translational Research
IO Biotech APS

Anne Vaslin Chessex
Associate Director, Pharmacology & Screening
Debiopharm

Niina Veitonmäki
Director In Vivo Immune-Oncology
Molecular Partners AG

Lead Partner:

CrownBio
CONNECTING SCIENCE TO PATIENTS

Programme Partners:

The Jackson Laboratory
Leading the search for tomorrow's cures

CHAMPIONS ONCOLOGY

hansonwade

Tel: +44 (0)20 3141 8700 **Email:** info@hansonwade.com

Tumour Models @Predict_models

7th PREDICT: TUMOURMODELS LONDON

Tumour Models London 2018
December 4-6, London, UK

WHAT TO EXPECT

100+ Attendees

21 Case Studies

2 Deep Dives

8+ Hours of Networking

Arming Decision Making Through Model Confidence

Returning for its 7th year, PREDiCT: Tumour Models London remains dedicated to exploring the continued application of oncology and IO models to enhance the translation of cancer therapies from bench to patient.

Sitting at the interface of innovation in model development and therapeutic application, Tumour Models London will merge strategic perspectives from bio-pharma with new insights of emerging therapeutic programmes.

The event offers a unique opportunity to plug into a ready-made network of peers who continue to redefine this area and have already solved the variety of challenges you're facing.

Where other conferences require you sit and listen quietly, we've redesigned the meeting format to facilitate an environment of open knowledge sharing and debate, all to ensure you'll leave with actionable takeaways on model utility and applicability.

Join stakeholders from across pharma, academia and model developer organizations in actively assessing how the industry is tackling drug attrition through the use of *in vitro* & *in vivo* models.

Presentations will Explore

1. Strategies centering on model selection and characterization to optimize preclinical and translational decision making

2. Answering which model systems are truly predictive for the identification, assessment & validation of patient-level responses to immunotherapies

3. The predictive validity of emerging in-vitro based models for discovery and understanding drug response

4. Rationally modelling next-generation immune-therapies with an eye towards toxicity and resistance

Tel: +44 (0)20 3141 8700 Email: info@hansonwade.com
www.tumour-models.com Tumour Models @Predict_models
hansonwade

Expert speakers

Alexander Koers
Senior Scientist
F-Star Biotechnology

Alison Mackinnon
Director of Research
Galecto Biotech

Anita Seshire
Head of Laboratory Cellular Pharmacology & Translational Innovation Platform Oncology
Merck KgGA

Anne Vaslin Chessex
Associate Director, Pharmacology & Screening
Debiopharm

Ayako Pedersen
Head of Translational Research
IO Biotech APS

Bigot Ludovic
Project manager
Gustave Roussy Institute

Cristina Bertinetti-Lapatki
Principal Scientist, Investigative Safety
Roche

Dik C. van Gent
Associate Professor
Erasmus MC

Elad Katz
Lead Biologist
Dundee University

Elizabeth Hardaker
Head, Oncology In Vivo Pharmacology Group
AstraZeneca

Fabien Garcon
Scientist I
MedImmune

Gavin Bennett
Head of Preclinical Development
Bicycle Therapeutics

Giorgio Seano
Head of Tumor Microenvironment Lab
Institut Curie Research Center

Jayesh Majithiya
Senior Scientist
Crescendo Biologics

Jean Viallet
CEO
Inovotion

Marleen Van Loenen
Director - Non-Clinical Development
Gadeta

Maryland Franklin
Vice President – Scientific Development
MI Bioresearch

Niina Veitonmäki
Director In Vivo Immune-Oncology
Molecular Partners AG

Rajendra Kumari
General Manager & CSO
Crown Bioscience

Ralph Gareus
Director Business Development Europe
The Jackson Laboratories

Roberto Speck
Professor
University Hospital of Zurich

Bruce Ruggeri
CSO
Champions Onoclogy

Tao You
PK/PD Modeller & Data Scientist
Beyond Consulting Ltd.

Conference Day One | December 5th 2018

Niina Veitonmäki
Director In Vivo Immune-Oncology
Molecular Partners AG

8.20 **Chairperson's Opening Remarks**

Addressing The Demand for Clinically Relevant Models

Rajendra Kumari
General Manager & CSO
Crown Bioscience

8.30 **Tumour Microenvironment, Heterogeneity and Clinically Relevant Models**

- Addressing the demand for clinically relevant models for understanding disease progression & identifying responsive patient populations
- Developing 3D systems and PDX modelling to enhance translational success
- Adopting the right models across oncology therapeutics

Elad Katz
Lead Biologist
Dundee University

8.55 **What Are We Modelling, and What Should We be Modelling For?**

- Exploring whether current models provide the necessary tools needed to achieve clinical success
- Discussing model-benchmarking and why this is hampering our quest for new drugs
- Highlighting recent progress in the development of in-vitro based systems and their applicability for biomarker discovery and validation

Ralph Gareus
Director Business Development Europe
The Jackson Laboratories

9.20 **Utilising Sophisticated Mouse Models to Better Understand the Pathways and Mechanisms of Emerging Immune Therapies**

- Understand how animal models can provide accurate in vivo conditions to mimic the natural tumour environment
- Hear the latest case studies in the use and relevance of humanised mice
- Explore how to successfully use humanised models to select combinations of immunotherapies

Elizabeth Hardaker
Head, Oncology In Vivo Pharmacology Group
AstraZeneca

9.45 **Identifying Preclinical Models to Support Immune Targeting Therapeutic Agents**

- What is changing in our requirements for immune targeting therapeutic agents?
- What are the current models available to support this?
- How are we advancing model development to enable novel model development?

Elad Katz
Lead Biologist
Dundee University

Rajendra Kumari
General Manager & CSO
Crown Bioscience

Ralph Gareus
Director Business Development Europe
The Jackson Laboratories

Elizabeth Hardaker
Head, Oncology In Vivo Pharmacology Group
AstraZeneca

9.10 **Session Q&A Panel**

- How can we better design and develop models which can replicate a more natural and translationally relevant tumour microenvironment
- In which situations can syngeneic mice, GEMMs and strategies of immune system humanisation in mice add most value to preclinical development
- With which systems have we seen the most success in understanding the mechanisms underlying the complex interactions between the immune system and cancer?
- What are the key challenges using classic syngeneic models for drug discovery that GEMM, 3D and other systems can fulfil?

10.30 **Speed Networking**

11.00 **Morning Refreshments**

Characterizing the Utility of Microphysiological Models in Oncology and IO Research

Jean Viallet
CEO
Inovotion

11.30 Early In-Vivo Identification of Low Value Molecules

- How to use INOVOTION technology to open new perspectives of in vivo screening for anti-caner treatments
- Why chick embryo model has several advantages for drug discovery in oncology
- Chick embryo model fills the gap between in vitro and mouse model but is it possible to predict mouse data from chick embryo results

Gavin Bennett
Head of Preclinical Development
Bicycle Therapeutics

11.45 Modelling Efficacy with Bicycle Toxin Conjugates: the Challenges of PK/PD and In-Vitro In-Vivo Correlation

- Exploring model limitation, responses and predictability of in-vivo response
- Describing models and key considerations for experimental design when dealing with scheduling and cycling of IO & Chemotherapeutic agents
- Exploring the potential of in vitro models in serving as a platform for clinically relevant drug development in a timely and cost effective manner

Cristina Bertinetti-Lapatki
Principal Scientist, Investigative Safety
Roche

12.10 Safety Assessment of Immunomodulatory Drugs Using Microfluidic and Static Based In Vitro Models

- Exploring where advanced cell models can win
- Highlighting its applications for the evaluation and development of effective anticancer agents and implications for patient avatars s
- Assessing general challenges of in vitro systems & safety prediction

Gavin Bennett
Head of Preclinical Development
Bicycle Therapeutics

Cristina Bertinetti-Lapatki
Principal Scientist, Investigative Safety
Roche

12.35 Session Q&A Panel

- Does context of use for microphysiological systems remain a critical factor in achieving success within industry?
- What are the greatest opportunities and challenges in adoption of more predictive 3D models?
- What key components should be considered when developing a predictive 3D model?

12.45 Lunch Break

Modelling Cancer Drug Response In Vitro

Fabien Garcon
Scientist I
MedImmune

1.45 Using Patient Derived Tumour Slices to Study the Tumour Microenvironment

- Exploring how tumour slices can capture the entire TME in vitro and enable the evaluation of donor differential response
- Testing hypotheses for lead validation and model development
- Understanding mechanisms of action of biologic therapies immune-oncology arena

Dik C. van Gent
Associate Professor
Erasmus MC

2.10 Predicting Clinical Outcomes Through the Development 3D Assays on Tumour Biopsies

- Revealing how 3D tumour tissue slices can be cultured and treated as ex-vivo as a predictive model for therapy response
- Clinical validation of ex-vivo assays on tumor biopsies is ongoing
- Exploring how the miniaturization and standardization in a cancer-on-chip set up may enable truly personalized medicine (testing multiple treatments, co-clinical trial)

Fabien Garcon
Scientist I
MedImmune

Dik C. van Gent
Associate Professor
Erasmus MC

2.35 Session Q&A Panel

- What key components should be considered when developing in vitro tumour models to ensure that they are more physiologically relevant?
- How do we validate, scale and automate PDX, tissue slice and other advance culture models?
- Should we define their context use within the translational and early clinical phases?

2.45 **Afternoon Refreshment Break**

Enhancing the Translational Confidence of Developing Immunotherapies

Alexander Koers
Senior Scientist
F-Star Biotechnology

3.45 **Preclinical Models to Identify First-in-class IO Bispecific Antibodies**

- mAb² ™, a bispecific antibody format that allows a "plug and play" modular strategy
- F-star's preclinical approaches for discovery of bispecific antibodies
- Understanding strengths and limitations of preclinical models

Maryland Franklin
Vice President – Scientific Development
MI Bioresearch

4.10 **Syngeneic Models of Breast Cancer: Effects of Immune Modulatory Agents in Classically "Cold" Tumours**

- How to select between murine breast cancer models
- Preclinical immunotherapy approaches in murine breast cancer models

Giorgio Seano
Head of Tumor Microenvironment Lab
Institut Curie Research Center

4.25 **Intravital Microscopy of Glioblastoma Models: Dynamics and Targeting of Vessel Co-option and Physical Forces**

- Revealing how the in vivo study of tumor dynamics lets us discover novel clinically-relevant tumor vulnerabilities
- Understanding and modulating the vascular tumor microenvironment in glioblastoma
- Investigating the whole brain instead of the tumor only in order to shed lights on pathophysiological mechanisms affecting the patient's quality of life

Alison Mackinnon
Director of Research
Galecto Biotech

4.50 **Galectin-3 as a Target for Anticancer Therapy**

- Galectin-3 modulates several processes involved in tumour growth and metastasis.
- Demonstrating how inhibitors of galectin-3 show promise as anti-cancer therapies.
- Showcasing data revealing how Galectin-3 inhibitors boost response to immune checkpoint inhibitors

Alexander Koers
Senior Scientist
F-Star Biotechnology

Giorgio Seano
Head of Tumor Microenvironment Lab
Institut Curie Research Center

Alison Mackinnon
Director of Research
Galecto Biotech

5.15 **Session Q&A Panel**

- How can models better replicate a more natural and translationally relevant tumour microenvironment?
- What are the fundamental differences in immune composition, tumour microenvironments and disease progression between mice and humans? How can we overcome these and further minimise or account for this gap?
- What role should preclinical metastasis models play in confirming the role of the TME & efficacy of therapeutics?
- What is the biology and clinical significance of the immune component such as myeloid-derived suppressor cells, macrophages etc. in the TME

5.45 **End of Conference Day One**

Kindly Hosted By:

CrownBio
CONNECTING SCIENCE TO PATIENTS

Evening Drinks Reception & Poster Session

Conference Day Two | 6th December 2018

PDX Models as a Platform for Clinically Relevant Drug Development

8.30 **Clinically-Relevant Ex Vivo and in Vivo PDX Platforms for Better, More Predictive, Oncology Drug Discovery**

Bruce Ruggeri
CSO
Champions Oncology

- Large collections of PDX models allow for more resolute efficacy predictions and the discovery of new therapeutic targets
- Why creating robust systems of myeloid engraftment allow for expanded PDX screening with a wider scope of therapeutics agents
- Combining clinical trials with companion PDX studies to guide follow-on trial design

8.55 **MATCH-R, Development of Preclinical Models from Patient with Acquired Resistance to Targeted Therapy**

Bigot Ludovic
Project manager
Gustave Roussy Institute

- Highlighting the development of a panel of PDX models derived from biopsies collected at the stage of acquired resistance
- Demonstrating how these PDX models will be used to improve knowledge on the mechanisms underlying resistance to treatment
- Exploring the impact on evaluating response to new treatments

9.20 **Use Of PDX Models in Translational Research to Identify Predictive Biomarkers & Support Clinical Development: Case Study of a FGFR Inhibitor**

Anne Vaslin Chessex
Associate Director, Pharmacology & Screening
Debiopharm

- Exploring a case study of a FGFR inhibitor
- Highlighting the conduct of an in vivo mouse trial (data interpretation - dealing with models with different growth characteristics)
- Showcasing the translation to the clinic

Anne Vaslin Chessex
Associate Director, Pharmacology & Screening
Debiopharm

Bigot Ludovic
Project manager
Gustave Roussy Institute

Bruce Ruggeri
CSO
Champions Oncology

9.45 **Session Q&A Panel**

- In which situations should PDX be used as a suitable surrogates for screening novel immunotherapies?
- How should we advance PDX tumour biology platforms for drug advancement?
- Does pre-clinical success with PDX models equal clinical translatability?
- How can –omic based techniques be utilised to characterize PDX models and enhance the translational assessment of immunotherapies?

10.00 **Morning Refreshment Break**

Accelerating the Development of Personalised Cancer Therapy

11.00 **Preclinical Animal Models for Therapeutic Clinical Dose Predictions and PD Assessment**

Niina Veitonmäki
Director In Vivo Immune-Oncology
Molecular Partners AG

- Utilizing animal models to explore compound activity, mechanism of action and discover biomarkers
- Exploring the need of translational strategies to identify biomarkers of responses and predict human dosing

11.25 **Human Derived 3D Tissue Based Preclinical Models Understand Mechanisms of Resistance And Identify Biomarkers Of Response**

Anita Seshire
Head of Laboratory Cellular Pharmacology & Translational Innovation Platform Oncology
Merck KgGA

- Highlighting the importance of understanding human tumour microenvironment
- Revealing strategies based on utilizing ex vivo tumour explant cultures and cancer organoid-based models for translational research in immune-oncology

Niina Veitonmäki
Director In Vivo Immune-Oncology
Molecular Partners AG

11.50 **Session Q&A Panel**

Anita Seshire
Head of Laboratory Cellular Pharmacology & Translational Innovation Platform Oncology
Merck KgGA

- Which model systems are most suitable for the identification, assessment & validation of biomarker candidates?
- Which translational tools are truly predictive of what kind of patients are most likely to respond to immunotherapies (or at least narrow) populations to focus on in Ph1?
- Are we going to have to continue to rely on empirical exploration large All-comer Ph1 studies?

12.00 Interactive Roundtable Discussions

1. Modelling the MoA of IO Combinations

- How do we better handle the unexpected?
- What strategies should we employ to avoid immune-related adverse events and guide the future combination cancer immunotherapy
- What emerging models should we invest into to enhance the predictive confidence of combination testing and general de-risking of cytotoxic, targeted and IO clinical programs

2. Methods for Modelling & Overcoming Resistant Tumours

- Discussing biological factors associated with response and resistance to in human solid tumours
- Reviewing the strengths and predictive validity of current systems in modelling patient-level responses and resistance

3. Creating Designer Animal Models

- Exploring advances in CRISPR genome editing for advanced in vivo editing with optimised specificity in transgenic mice
- Highlighting the current limitations of using CRISPR for insertions for higher efficiency of desired edits

4. Addressing Validation and Scaling Challenges for 3D Models

- What methods should be utilised to evaluate and validate new technologies for advanced 3d in vitro immuno-oncology models?
- Assessing strategies for model expansion and scaling

12.45 Round Table Moderator Feedback Panel

1.00 Lunch & Networking Break

Overcoming Preclinical Development Hurdles for Novel Drug Modalities

Jayesh Majithiya
Senior Scientist
Crescendo Biologics

2.00 Developing Humabody: VH Fragments for Oncology Applications

- Discussing the development of the TKO Crescendo Mouse and its role enabling the robust production of humanised VH fragments
- Examining with case how humabodies offer a unique combination of benefits for generating novel multivalent formats
- Exploring recent model and distribution data showing their increased tissue and tumour penetration

Ayako Pedersen
Head of Translational Research
IO Biotech APS

2.25 Developing Immune Modulating Vaccines

- Exploring how self-reactive T cells can act as targets of immune modulating vaccines
- Showcasing preclinical studies to evaluate the potential of immune modulating vaccines to alter the TME and impact immune inhibitory pathways
- Fast-track from bench to bedside

Marleen Van Loenen
Director - Non-Clinical Development
Gadeta

2.50 Assessing the Safety and Efficacy of Gamma-Delta TCR's

- Exploring general challenges involved in preclinical safety and efficacy testing of TCR's
- Highlighting preclinical models that are allowing for a greater level of prediction of anti-tumour efficacy and toxicity
- Presenting on the model strategy and impact of adopting organoids and 3D tissue slices to test safety in the light of efficacy

Jayesh Majithiya
Senior Scientist
Crescendo Biologics

Ayako Pedersen
Head of Translational Research
IO Biotech APS

Marleen Van Loenen
Director - Non-Clinical Development
Gadeta

3.15 Session Q&A Panel

- In which situations do traditional models prove unsuitable for safety assessments beyond the checkpoint landscape
- Proper design, execution and reporting of animal model results help to make preclinical data more reproducible and translatable to the clinic

3.30 Chairs Closing Remarks & Close of Conference

PRECONFERENCE DEEP DIVES

Pre-Conference Day | December 4

Deep Dive A

Using Translational Modelling to Evaluate Preclinical Tumour Models

9:00am – 12:00pm

Discovery and development of cancer treatments (e.g. radiotherapy, chemotherapy, cell-directed targeted therapy, immune therapy) require PK/PD modelling for robust experimental design and unambiguous data interpretation.

This short course will introduce how translational PK/PD modeling for chemotherapy and cell-directed targeted therapy can be used to relate preclinical data with clinical response. We will also discuss the basics of PK/PD modelling that are relevant to evaluating novel immuno-oncology treatments. It will help attendees to learn about dose selection, estimation of therapeutic window, and translational sciences based on PK/PD modeling.

Topics to be explored:

- How do we defne the quantitative relationship between preclinical efficacy and clinical activity for these treatments?
- Is it possible to set minimum preclinical efficacy criteria to qualify a novel treatment for clinical success?
- How to apply translational modelling framework to best support drug projects? Where does it add value?
- Which ideas can be borrowed to support immuno-oncology projects?

Workshop Leader

Tao You
PK/PD Modeller & Data Scientist
Beyond Consulting Ltd.

Deep Dive B

Humanised Mice Models as a Translational Tool for Immuno-Onocology

1:00pm – 4:00pm

Recent breakthroughs involving humanized mice have elevated the translational quality of these models within preclinical research. As such these models have become highly relevant for fundamental research to understand the function of the human immune system and in assessing cancer immunology and immunotherapies.

This workshop will explore the different strategies of immune system humanization in mice as well as to review challenges, insights, and future directions for mouse and humanized models within oncology.

Topics to be explored:

- State of the art of humanized mice
- Immune reactivity / responses in humanized mice
- What did we learn from viral infection studies in humanized mice
- State of the art of humanized mice for studying tumours

Workshop Leader

Roberto Speck
Professor
University Hospital of Zurich

SPONSORS

Lead Partner

CrownBio
CONNECTING SCIENCE TO PATIENTS

Our mission is to provide the "gold-standard" collection of well characterised models and services for drug discovery to help our clients reduce the attrition rate of candidate compounds in the clinic, before they enter the clinic. Crown Bioscience, Inc. is a Preclinical CRO with expertise in the disease areas of Oncology and Metabolic Disease. We are known for the breadth and quality of our in vitro and in vivo models, as well as our ability to help clients quantify the real efficacy and pharmacological profile of their candidate before they move into the clinic.

www.crownbio.com

Programme Partner

The Jackson Laboratory
Leading the search for tomorrow's cures

The Jackson Laboratory is a leading provider of cancer mouse models and in vivo oncology services and a National Cancer Institute designated Cancer Center. Drawing on decades of research experience we provide capabilities around model selection, husbandry and customizable oncology studies to help clients and researchers evaluate novel anti-cancer therapies. Our diverse oncology study protocols range from traditional xenograft services to PDX cancer models and advanced humanized mouse models for immuno-oncology drug development.

www.jax.org

Programme Partner

CHAMPIONS ONCOLOGY

Champions Oncology was founded by renowned specialists in the field of cancer diagnosis, treatment, and research. The Champions Oncology team is comprised of seasoned oncolog rofessionals passionately dedicated to working to accelerate oncology drug development, improve treatment outcomes and extend lives. Our core platform, the Champions TumorGraft™ offers an enhanced xenograft mouse avatar model for growing and testing human tumours. Champions Personalized TumorGrafts™ empower patients and physicians using an in vivo xenograft mouse avatar based diagnostic model that has shown to be predictive of a patients' clinical response to cancer treatments and anticancer therapies

www.championsoncology.com

Spotlight Partner

MI Bioresearch
Advancing Your Preclinical Oncology

MI Bioresearch (MI), a preclinical oncology service provider, offers in vitro services, oncology pharmacology, in vivo imaging, and focal radiation to support research programs. Our team explores the effects of your drugs and biologics using both human and syngeneic models and multi-modality imaging systems. MI provides you with decision-driving data to help advance your drug candidate toward the next cancer research breakthrough. One Focus. One Purpose. Oncology Research.

www.mibioresearch.com

Spotlight Partner

inovotion
WHICH MOLECULE WILL STAND OUT

INOVOTION is a biotech company which offers you a unique in vivo technology dedicated to anti-cancer treatment evaluations and early toxicity studies. Our Fast, Sensitive, Reliable and Affordable assay will save you time and money, to give you a clear competitive advantage.

www.inovotion.com

Partner

VIVOPHARM
A CGI COMPANY

vivoPharm, a CGI company (NASDAQ:CGIX), is a successful and fast-growing precisition contract research organization (CRO) providing integrated preclinical services from bench to bedside worldwide. We use our experience and expertise to assistin the planning of and conducting tailored studies, from discovery stages through to clinical development and beyond. We're a unique IO precision service organization active in per-clinical and clinical services. All work is carried out under well-defined standard operating procedures (SOPs) by highly qualified technicians in state of-the-art laboratories in seven locations.

www.vivopharm.com.au

BECOME A PARTNER

Diane McKenna
Commercial Director, PREDiCT
Tel: +44 (0)20 3141 8700

READY TO REGISTER?

3 EASY WAYS TO BOOK

www.tumour-models.com/register/

Tel: +44 (0)203 141 8700

Email: register@hansonwade.com

1. Optimize model selection & characterization
2. Benchmark against leading pharmaceutical organizations
3. Explore model advances & drive translational decision making

Team Discounts*

- **10% discount – 2 delegates**
- **15% discount – 3 delegates**
- **20% discount – 4 or more delegates**

Please note that discounts are only valid when two or more delegates from one company book and pay at the same time.

Model and Service Providers Pricing	Register before Friday, 5th October	Standard Price
GOLD Conference + 2 Workshops	**£3399** (save £600)	**£3799** (save £200)
SILVER Conference + 1 Workshop	**£2899** (save £500)	**£3299** (save £100)
BRONZE Conference Only	**£2399** (save £400)	**£2799**
Workshops (Each)	**£599**	

Drug Developers Pricing	Register before Friday, 5th October	Standard Price
GOLD Conference + 2 Workshops	**£2599** (save £600)	**£2999** (save £200)
SILVER Conference + 1 Workshop	**£2199** (save £500)	**£2599** (save £100)
BRONZE Conference Only	**£1799** (save £400)	**£2199**
Workshops (Each)	**£499**	

*A small-biotech discounted rate is available to allow newer, less established companies to attend this meeting.

Email info@hansonwade.com to enquire about the rate or apply. Eligibility criteria states that the company needs to be less than 8 years old and with less than 25 full time employees. Model and service providers are excluded. All bookings at this rate are subject to organizer approval. T&Cs apply.

**An additional discount is available for academics. Email info@hansonwade.com to enquire about the rate or apply.

***All prices subject to 20% VAT

VENUE

Park Plaza London Riverbank
18 Albert Embankment, London
SE1 7TJ, United Kingdom

For further information or assistance, please visit www.parkplaza.com